Bookmark and Share

Aaron P Rapoport
 

Aaron P Rapoport M.D.

Academic Title: Professor
Primary Appointment: Medicine
Additional Title(s): The Gary Jobson Professor in Medical Oncology; Director of Lymphoma Gene Medicine, Marlene and Stewart Greenebaum Cancer Center
ARAPOPORT@umm.edu
Location: UMMC, Room N9E12
Phone: (410) 328-1230
Fax: (410) 328-1975

Research Interests:

My clinical interests involve the treatment of hematologic malignancies, including acute and chronic leukemias, lymphomas and myeloma. Treatment approaches include both standard-dose chemotherapy and immunotherapy as well as high-dose therapy combined with autologous or allogeneic (donor) stem transplantation.
 
My clinical research interests concern the development of novel strategies for re-building immune system function after autologous stem cell transplantation for myeloma and leukemia and specifically involve the use of post-transplant cellular and vaccine-based immunotherapy. The goal of this work is to improve upon post-transplant outcomes including the duration of disease responses and the prevention of infections.

In 2006, I was chosen by the Leukemia & Lymphoma Society to receive their prestigious Stohlman Scholar Award for outstanding contributions to the advancement of blood cancer research. The Stohlman award is given to Society Scholars who are in the fifth year of their research. Society Scholars are highly qualified investigators who have demonstrated their ability to conduct original research bearing on leukemia, lymphoma or myeloma.


Publications:

*Rapoport AP, Lifton R, Constine LS, et al.  Autotransplantation for relapsed or refractory non-Hodgkin's lymphoma (NHL):  Long-term follow-up and analysis of prognostic factors.  Bone Marrow Transplant, 19:883-890.1997.

*Rapoport AP, Miller, Watelet LF, Linder T, Eberly S, Raubertas RF, Lipp J, Duerst R, Abboud CN, Constine L, Andrews J, Etter MA, Spear L, Powley E, Packman CH, Rowe JM, Schwertschlag U, Bedrosian C, Liesveld JL. Analysis of factors that correlate with mucositis in recipients of autologous and allogeneic stem cell transplant. J Clin Oncol,  17(8):2446-2453.1999.

Rowe JM, Rapoport AP, Ryan DH, Nillson BI, Duerst RE, Packman CH, Abboud CN, DiPersio JF, Linder T, Wang N, Simonsson B, Liesveld JL.  Treatment of chronic myelogenous leukemia with autologous bone marrow transplantation followed by roquinimex.  Bone Marrow Transplant, 24:1057-1063. 1999.

Fassas AB-T, Rapoport, AP, Cottler-Fox M, Chen T, Tricot G.  Encouraging preliminary results in 12 patients with high-risk haematologic malignancies by omitting Graft-versus-Host disease prophylaxis after allogeneic transplantation. British Journal of Haematology, 111:662-667. 2000.

*Rapoport AP, Meisenberg B, Fassas A, Frankel SR, Mookerjee B, Takebe N, Fenton R, Badros A, Kennedy A, Jacobs M, Hudes R, Ruehle K, Smith R, Kight L, Chambers, S, MacFadden M, Cottler-Fox M, Sarkodee-Adoo C, Chen T, Phillips G, Tricot G.  Autotransplantation for advanced lymphoma and Hodgkin disease followed by post-transplant rituxan/GM-CSF or radiotherapy and consolidation chemotherapy. Bone Marrow Transplant, 29: 303-312. 2002.

Sarkodee-Adoo C, Sotirescu D, Sensenbrenner L, Rapoport AP, Cottler-Fox M, Tricot G, Ruehle K, Meisenberg B.  Thrombotic microangiopathy in blood and marrow transplant patients receiving tacrolimus or cyclosporine A.  Transfusion, 45:78-84. 2003. 

Bolanos-Meade J, Karp J E, Guo C, Sarkodee-Adoo CB, Rapoport AP, Tidwell MT, Buddharaju LN, Chen TT. Timed sequential therapy of acute myelogenous leukemia in adults:  A phase II study of retinoids in combination with the sequential administration of cytosine arabinoside, idarubicin, and etoposide. Leukemia Research, 27:313-321. 2003.

Liesveld JL, Abboud CN, Harbol A, McNair II C, Rosell K, Menon A, Smith A, Rapoport AP. Flavonoid effects on normal and leukemic cells.  Leukemia Research, 27:517-527. 2003.

*Rapoport AP, Levine BL, Badros A, Meisenberg B, Ruehle K, Nandi A, Rollins S, Natt S, Ratterree B, Westphal S, Mann D, June CH. Molecular remission of CML after autotransplantation followed by adoptive transfer of costimulated autologous T-cells. Published on-line; doi:10;1038/sj.bmt.1704317, 10/27/03. Bone Marrow Transplantation, 33:53-60. 2004.

#Nandi A, Tidwell M, Karp J, Rapoport AP.  Protein expression of PDZ-binding kinase (PBK) is up-regulated in hematologic malignancies and strongly down-regulated during terminal differentiation of HL-60 leukemic cells. Published on-line; doi:10.1016/j.bcmd.2003.10.004, 11/19/03. Blood Cells, Molecules and Diseases, 32:240-245.  2004. 

Phillips GL, Meisenberg BR, Adams VR, Badros AZ, Brunner JL, Fenton RG, Filicko J, Grosso D, Hale GA, Howard DS, Johnson VP, Kniska A, Marshall KW, Mookerjee B, Nath R, Rapoport AP, Sarkodee-Adoo C, Takebe N, Vesole DH, Wagner JL, Flomenberg N. Activity of single-agent melphalan 220-300mg/m2 with amifostine cytoprotection and autologous hematopoietic stem cell support in non-Hodgkin’s and Hodgkin lymphoma.  Bone Marrow Transplantation, 33(8):781-7.  2004.

Gojo I, Sarkodee-Adoo C, Meisenberg B, Guo C, Fassas A, Rapoport AP, Cottler-Fox M, Heyman M, Tricot G. High-dose cyclophosphamide with or without etoposide for mobilization of peripheral blood progenitor cells in patients with multiple myeloma:  efficacy and toxicity.  Bone Marrow Transplantation, 34(1):69-76. 2004.

Phillips G, L, Adams VR, Reece DE, Badros A, Brunner J, Filicko J, Grosso D, Hale GA, Howard DS, Johnson VP, Kniska A, Marshall KW, Meisenberg B, Nath R, Reed E, Rapoport AP, Takebe N, Vesole DH, Wagner JL, Flomenberg N. Amifostine and autologous hematopoietic stem cell support of escalating-dose melphalan:  A phase I study. Biology of Blood and Marrow Transplantation, 10(7):473-483. 2004.

Thomas L, Stamberg J, Gojo I, Ning Y, Rapoport AP. Double minute chromosomes in monoblastic (M5) and myeloblastic (M2) acute myeloid leukemia: 2 case reports and a review of literature. American Journal of Hematology 77:44-61. 2004.

*Rapoport AP, Badros A, Kiggundu E, Akpek G, Meisenberg B, Hakimian R, Mannuel H, Takebe N, Fenton R, Bolanos-Meade J, Heyman M, Gojo I, Ruehle K, Natt S, Ratterree B, Withers T, Sarkodee-Adoo C, Phillips GL, Guo C, Tricot G. Autologous stem cell stransplantation followed by consolidation chemotherapy for relapsed or refractory Hodgkin Lymphoma. Bone Marrow Transplantation, 34(10):883-890. 2004.

Takebe N, Cheng X, Wu S, Bauer K, Goloubeva OG, Fenton RG, Heyman M, Rapoport AP, Badros A, Shaughnessy J, Ross D, Meisenberg B, Tricot G. Phase I clinical trial of the inosine monophosphate dehydrogena inhibitor mycophenolate mofetil (cellcept) in advanced multiple myeloma patients. Clinical Cancer Res. 10(24): 8301-8. 2004.

Kasamon K, Drachenberg CI, Rapoport AP, Badros AZ. Catastrophic antiphospholipid syndrome: atypical presentation in the setting chronic graft versus host disease: case report and review of the literature. Haematologica/The Hematology Journal. e-cases, February/March 2005.

Badros AZ, Goloubeva O, Rapoport AP, Ratterree B, Gahres N, Meisenberg B, Takebe Naoko, Heyman M, Zwiebel J, Streicher H, Gocke CD, Tomic D, Flaws JA, Zhang B, Fenton R.  Phase II sytudy of G3139, Bcl-2 Antisense, in combination with dexamethasone and Thalidomide in relapsed multiple myeloma patients.  Journal of Clinical Oncology.  10.1200, 14.381. 2005.

Akpek G, Jain M, Titanji R, Rapoport, AP, Wang W, Gocke C, Cross A, Akpek G. A fatal clostridium infection in an allogeneic stem cell transplantation recipient. Bone Marrow Transplantation, 36(5): 455-457. 2005.

Nandi A, Rapoport AP. Expression of PDZ-binding kinase (PBK) is regulated by cell cycle-specific transcription factors E2F and CREB/ATF.  Leukemia Research. Online publication date: 16 September 2005 doi: 10.1016/j.leukres.2005.08.011. 

Crowley JA, Wang T, Rapoport AP, Ning Y. Detection of MOZ-CZB fusion in acute myeloid leukemia with 8; 16 translocation. Leukemia, 19(12): 2344-2345. 2005; Online publication date: September 29, 2005;doi: 10.1038/sj.leu.2403971. 

*Rapoport AP, Stadtmauer EA, Aqui N, Badros AZ, Cotte J, Chrisley L, Veloso E, Zheng Z, Westphal S, Mair R, Chi Nina, Ratterree B, Pochron MF, Natt S, Hinkle J, Sickles C, Sohal A, Ruehle K, Lynch C, Zhang L, Porter D, Luger S, Guo C, Fang H, Blackwelder W, Hankey K, Mann D, Edelman R, Frasch C, Levine BL, Cross A, June H.  Restoration of immunity in lymphopenic cancer patients by vaccination and adoptive T cell transfer. Nature Medicine, 11(11): 1230-1237, 2005; Online publication date October 16, 2005; doi: 10.1038/nm1310.

Gojo I,  Meisenberg B, Guo C, Badros AZ, Fassas A, Murthy A, Fenton R, Takebe N, Heyman M, Philips GL, Cottler-Fox M, Sarkodee-Adoo C, Ruehle K, French T, Tricot G, Rapoport AP. Autologous stem cell transplantation followed by consolidation chemotherapy for patients with multiple myeloma. Bone Marrow Transplantation. Online publication date October 24, 2005; doi: 10.1038/sj.bmt.1705192.

Badros A, Weikel D, Salama A, Goloubeva O, Schneider A, Rapoport AP, Fenton R, Hahres N, Sausville E, Ord R, Meiller T. Osteonecrosis of the jaw in multiple myeloma patients: clinical features and risk factors.  Journal of Clinical Oncology.In press.